🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Observation from #ENZAMET ✅ Adding enzalutamide to TS plus docetaxel had the same treatment effect as adding abiraterone (#PEACE1) to darolutamide (#ARASENS) to TS + docetaxel in pts presenting with synchronous mHSPC authors.elsevier.com/c/1gpmh5EIIgLp…

Ab#4579 #ASCO23 ASCO : The efficacy of sacituzumab govitecan (SG) in locally advanced /mUC #bladdercancer by TROP-2 expression➡️similar ORR, outcomes in high and low tumor Trop-2 expression➡️SG activity independent of Trop-2 expression in UC👉tinyurl.com/y6htsrbc Congrats

ADCs enable an improved delivery of chemo, expanding its activity, but not necessarily decreasing its side effects. Why is that? How can we reduce the toxicities of ADCs? Glad to share our NatureRevClinOncol article on how to optimize the safety of ADC! 🧵 nature.com/articles/s4157…

HUGE NEWS: EV/Pembro combo tops platinum-based chemo, a SOC for 30+years, in 1L bladder cancer: a new era ….PFS/OS met! prnewswire.com/news-releases/…

< 3 weeks to #ESMO23, here is a📝 of 🔑abstracts for general onc that could change our SoC! - #ALINA - #LIBRETTO431 - #TROPIONLung01 - #MARIPOSA - #Ev302 - #CM901 - #LITESPARK005 - #KN756 - #CABINET - #CODEBREAK300 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ESMO - Eur. Oncology

JUST IN: via Streetinsider.com AMBASSADOR trial: Pembro extends DFS in high-risk urothelial/bladder cancer, an Alliance for Clinical Trials in Oncology National Cancer Institute study ! Andrea Apolo, M.D. Jonathan Rosenberg MD Matt Galsky OncoAlert streetinsider.com/dr/news.php?id…

Patients with #ctDNA clearance post PD1 #immunotherapy have better PFS & OS in this prospective study. Liquid biopsies may be used to rapidly & accurately determine clinical response, especially in the metastatic setting. nature.com/articles/s4159…

Register now Advanced Prostate Cancer Consensus Conference on apccc.org, no restrictions. Everyone interested in prostate cancer can register!

Constant TKI is NOT necessary in IO/TKI regimens. We need to prioritize strategies to de-escalate therapy for better QOL and possibly delaying resistance. Congrats to Roberto Iacovelli and the team for this important work.

#ESMO23 First results of #TAR210🥨 in patients with #NMIBC 👉 Promising efficacy data: ➡️ High recurrence free/complete response rate: 82% and 87% ➡️ 11/13 evaluable patients (BCG exp. HR #NMIBC) + 13/15 (IR #NMIBC) recurrence free #AntoniVilaseca JNJInnovative Medicine

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

#ESMO23 in numbers. Very impressive. Only missing the number of practice changing studies presented. ESMO - Eur. Oncology

JUST IN (and finally...): Pembrolizumab hits OVERALL SURVIVAL in KYN-564 adjuvant study in Kidney Cancer!!! The time has finally come... via Business Wire Dana-Farber Lank Center for Genitourinary Oncology Tom Powles OncoAlert Oncology Brothers OncLive.com Targeted Oncology UroToday.com Uromigos Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network

Ab#19 ASCO #GU24 by #MahaHussain👉tinyurl.com/5n8d36wa👉BRCAAway ph2 trial in 1L mCRPC with BRCA1/2 or ATM mut #prostatecancer 👉median PFS = 39 mo w/ olaparib + abi vs. 16 mo for sequencing of abi/ola or ola/abi 👇 Emmanuel Antonarakis OncoAlert UroToday.com Uromigos PCF Science

Interesting data on cabozantinib atezo in late CRPC with small PFS but no OS gain. To me this mirrors COMET1 where PFS also 6-7 mo but with higher costs. Hard to see what atezo has added here. #GU24 Neeraj Agarwal, MD, FASCO

PARP inhibitors (olaparib) increase the risk of MDS and AML. thelancet.com/journals/lanha…

New report on the risk of radiation necrosis with concurrent ADCs + brain RT. Incidence of symptomatic radiation necrosis was 27% with concurrent vs. 11% with non-concurrent ADC/RT (p=0.014). Important to temporarily stop the ADC before pursuing brain RT. link.springer.com/article/10.100…

🤔 How to choose a 1st line therapy in mCRPC patients nowadays ? 🚨 ➤ Some excellent suggestions from Christopher Sweeney, MBBS at Advanced Prostate Cancer Consensus Conference OncoAlert #APCCC24

Still the best definition of agressive variant prostate cancer so far #APCCC2024 Misha Beltran Ana Aparicio

There is more than PET-PSMA to monitor tumor response in advance PCa. Julien Van Damme Vassiliki Pasoglou fred lecouvet Anwar Padhani sciencedirect.com/science/articl…